
Modulari-T
Modulari-T is a YC Winter 2023 (W23) company. Based in Montreal, QC, Canada; San Francisco, CA, USA. Team of 4.
About Modulari-T
Summary
Modulari-T builds a synthetic gene platform for engineering immune and stem cells, targeting the structural limitations of first-generation CAR-T and cell therapies. Its two core technologies, MARC and MoVe, give engineered cells modular receptor control, on/off switching, and resistance to exhaustion, replacing the fixed receptor architectures that restrict current therapies to blood cancers and exclude solid tumors and chronic diseases. The platform is validated across five cell types and is designed to serve as foundational infrastructure for next-generation cell engineering broadly.
From the Y Combinator listing
We teach your immune system to attack and cure cancer
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Facts
- Healthcare / Healthcare -> Therapeutics
- Montreal, QC, Canada; San Francisco, CA, USA
- 4
- Active
- Early
Founders (2)
- David White
- Stephanie Mok
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works